Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 9/20 | 0.44 |
| ▸ | PPARD | Q03181 | 8/20 | 0.44 |
| ▸ | PPARA | Q07869 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5383333 | 1.00 | MAPK1 (0.44) | MAPK1L3MBTL1TSHRTDP1PPARG | |
| SCHEMBL5375724 | 0.94 | PPARG (0.46) | MAPK1L3MBTL1TSHRTDP1PPARG | |
| SCHEMBL5358773 | 0.83 | LMNA (0.55) | MAPK1PPARGPPARDPPARAALDH1A1 | |
| SCHEMBL5364045 | 0.83 | EPOR (0.54) | PPARGPPARAPTPN1 | |
| SCHEMBL5357749 | 0.78 | ITGB1 (0.43) | PPARGPPARDPPARAALDH1A1GAA | |
| SCHEMBL334386 | 0.77 | SLC7A5 (0.48) | MAPK1L3MBTL1TSHRTDP1ALDH1A1 | |
| SCHEMBL5360127 | 0.76 | NLRP3 (0.49) | MAPK1KDM4E | |
| SCHEMBL5379645 | 0.76 | PPARG (0.72) | PPARGPPARDPPARA | |
| SCHEMBL27871770 | 0.76 | PPARG (0.57) | MAPK1L3MBTL1TSHRTDP1PPARG | |
| SCHEMBL4073533 | 0.76 | ITGB1 (0.56) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | PPARG, NCOA4, PPARA | MAPK1 3706/4885L3MBTL1 3481/4885TSHR 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.